phrykt

Aldeyra Therapeutics, Inc. (ALDX): who owns it and who trades it

As of Nov 16, 2026, ALDX insiders reported 6 purchases worth $663K in the last 12 months. The largest buyer was Todd C Brady (CEO), with $418K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aldeyra Therapeutics

From the latest filings

Overall: about as much buying as selling. Funds and famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ALDX

108 funds and institutions reported ALDX shares worth $78.2M at the end of Q2 2026, about 61% of the company. The largest holder is Knoll Capital Management, LLC with 9.1%.

Funds and institutions (13F) 61%Everyone else 39%

10 largest owners, by share of the company

Knoll Capital Management, LLC9.1%
AQR Capital Management LLC6.2%
Kingdon Capital Management, L.l.c.4.4%
Vanguard Capital Management LLC3.9%
D. E. Shaw & Co., Inc.3.2%
Marshall Wace, LLP2.5%
683 Capital Management, LLC2.4%
Jane Street Group, LLC2.3%
BlackRock, Inc.2.1%
Qube Research & Technologies Ltd1.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Knoll Capital Management, LLC5.48M9.10%$11.7MNo change
AQR Capital Management LLC3.75M6.23%$8M+33%
Kingdon Capital Management, L.l.c.2.65M4.41%$5.6M+23%
Vanguard Capital Management LLC2.36M3.92%$5M-0%
D. E. Shaw & Co., Inc.1.94M3.22%$4.1M+38%
Marshall Wace, LLP1.51M2.50%$3.2M+1062%
683 Capital Management, LLC1.45M2.41%$3.1M-3%
Jane Street Group, LLC1.38M2.28%$2.9M+42%
BlackRock, Inc.1.26M2.09%$2.7M-67%
Qube Research & Technologies Ltd1.13M1.88%$2.4M+1196%
Acadian Asset Management LLC1.06M1.77%$2.3M+24%
Ardsley Advisory Partners LP975,0001.62%$2.1M+3%
Renaissance Technologies LLC882,0001.47%$1.9M+2%
Vanguard Portfolio Management LLC794,8631.32%$1.7M-2%
Goldman Sachs Group Inc725,4441.21%$1.5M+34%
Jacobs Levy Equity Management, Inc646,8401.07%$1.4M-19%
Morgan Stanley608,3211.01%$1.3M+17%
Geode Capital Management, LLC596,0290.99%$1.3M-52%
Dimensional Fund Advisors LP529,0830.88%$1.1M-15%
Gsa Capital Partners LLP472,5640.79%$1M+91%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ALDX insiders reported $663K of open-market purchases and $0 of sales.

Purchases, 12 months
$663K
6 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$418K$418KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Darlene M Deptula-HicksDirectorPurchase7,500$0.65$4.9KForm 4
Nov 11, 2026Richard DouglasDirectorPurchase200,000$0.64$129KForm 4
Nov 11, 2026Michael AlfieriPrincipal Financial OffiPurchase10,000$0.65$6.5KForm 4
Jun 3, 2026Todd C BradyCEOPurchase250,000$1.67$418KForm 4
Mar 19, 2026Richard DouglasDirectorPurchase70,000$1.40$98KForm 4
Mar 18, 2026Michael AlfieriPrincipal Financial OffiPurchase5,000$1.42$7.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Todd C BradyPresident and CEO, Director$418K–Jun 3, 2026
Richard DouglasDirector$227K–Nov 11, 2026
Michael AlfieriPrincipal Financial Officer$13.6K–Nov 11, 2026
Darlene M Deptula-HicksDirector$4.9K–Nov 12, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ALDX short interest

Moderate short interest. 5.2% of ALDX shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went down 58%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.16M ALDX shares were sold short, 5.2% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 917,902 shares, buying them all back would take about 3.4 trading days (days to cover).

Shares short, % of all shares

5.24%May 15Oct 3014.4%

Days to cover

3.4May 15Oct 309.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.16M5.24%-1%917,9023.4
Oct 15, 20263.19M5.28%-8%2.47M1.3
Sep 30, 20263.47M5.75%-4%1.15M3.0
Sep 15, 20263.60M5.97%+15%738,2494.9
Aug 31, 20263.12M5.17%-6%656,8494.8
Aug 14, 20263.32M5.51%-3%872,2803.8
Jul 31, 20263.42M5.69%-5%1.12M3.1
Jul 15, 20263.59M5.97%-37%1.81M2.0
Jun 30, 20265.68M9.43%-17%2.27M2.5
Jun 15, 20266.87M11.41%-14%1.10M6.3
May 29, 20267.95M13.21%+5%926,1778.6
May 15, 20267.58M12.60%+3%893,2658.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aldeyra Therapeutics company events

Aldeyra Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026AnnouncementAldeyra Therapeutics, Inc. announced that the Company has formally requested that the Division of Ophthalmology of the U.S. Food and Drug Administration submit a review jurisdiction request to the FDA’s Office of New Drugs recommending that review of the Company’s Investigational New Drug… Filing
  2. Sep 29, 2026AnnouncementAs reported under Item 7.01 of this Current Report on Form 8-K, on September 29, 2026, Aldeyra issued the Press Release to announce the intent to submit an FDRR, appealing the March 16, 2026 Complete Response Letter that denied approval of a New Drug Application for reproxalap for the treatment of… Filing
  3. Jul 30, 2026AgreementAldeyra Therapeutics, Inc. executed a lease agreement with Bradford Street, L.L.C. for approximately 4,067 square feet of office space located at 23 Bradford Street, Concord, Massachusetts. Filing
  4. Jul 15, 2026AnnouncementAldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Application (NDA) of reproxalap for the treatment of dry eye disease. Filing
  5. Jun 10, 2026LeadershipFollowing Aldeyra Therapeutics, Inc.’s 2026 annual meeting of stockholders, and based upon the recommendation of the Nominating/Corporate Governance Committee of the Board of Directors, the Board appointed Darlene Deptula-Hicks as a Class III director, with her initial term expiring at the… Filing
  6. May 1, 2026AnnouncementShared information with investors. Filing
  7. Apr 20, 2026LeadershipMartin J. Joyce, a member of the Board of Directors of Aldeyra Therapeutics, Inc., notified Aldeyra of his decision to not stand for re-election at the upcoming 2026 annual meeting of stockholders. Filing
  8. Apr 1, 2026AnnouncementAs previously disclosed, Aldeyra Therapeutics, Inc. entered into that certain Loan and Security Agreement, dated as of March 25, 2019, by and among the Company, Helio Vision, LLC, the several banks and other financial institutions or entities from time to time parties thereto and Hercules Capital… Filing
  9. Mar 17, 2026AnnouncementAs reported under Item 7.01 of this Current Report on Form 8-K, on March 17, 2026, Aldeyra announced receipt of the 2026 Complete Response Letter. Filing
  10. Dec 31, 2025LeadershipStephen G. Machatha, Ph.D. notified Aldeyra Therapeutics, Inc. of his decision to voluntarily resign from his position as Chief Development Officer of the Company to pursue other professional opportunities. Filing
  11. Dec 16, 2025AnnouncementAs reported in Item 7.01 of this Current Report on Form 8-K, on December 15, 2025, the Company issued the Press Release to announce the PDUFA extension for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Aldeyra Therapeutics financials

Famous investors that hold ALDX

4 of the 50 well-known investors we track reported holding ALDX in their latest 13F filing. The largest position is Jim Simons's, worth $812K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026660,336$812K0.0%-25%
Ken Griffin · Citadel AdvisorsQ3 2026245,677$302K0.0%-35%
Steve Cohen · Point72 Asset ManagementQ3 202663,465$78.1K0.0%-59%
Israel Englander · Millennium ManagementQ3 202661,739$75.9K0.0%-83%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ALDX in the last 120 days.

FiledHolderFormStake
Nov 12, 2026AQR Capital Management, LLC13G/A1.1%
Nov 12, 2026AQR Capital Management, LLC13G/A1.1%
Nov 6, 2026Barclays PLC13G5.5%
Nov 6, 2026Barclays PLC13G5.5%

Questions about Aldeyra Therapeutics, Inc. (ALDX) stock

Who owns the most ALDX stock?

The largest reported owner of Aldeyra Therapeutics, Inc. (ALDX) is Knoll Capital Management, LLC, with 9.1% of the company. In total, 108 funds and institutions reported holding ALDX at the end of Q2 2026, together about 61% of the shares. See the largest owners.

Are ALDX insiders buying or selling?

In the last 12 months, ALDX insiders reported 6 open-market purchases worth $663K and no sales. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in ALDX?

As of Oct 30, 2026, 3.16M ALDX shares were sold short, 5.2% of the shares outstanding, down 0.8% from the report before. At the average daily volume of 917,902 shares, buying them all back would take about 3.4 trading days (days to cover). See the history.

Which famous investors hold ALDX?

4 of the 50 well-known investors we track reported ALDX in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $812K. See all holders.

Executive pay

Aldeyra Therapeutics's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, up 20% from $3.9M the year before. In the last 12 months, Aldeyra Therapeutics's executives and directors bought $663K of stock on the open market and sold none.

Chief executive, total pay$4.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$4.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$848KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.